ABSTRACT
CONTEXT: Type 1 diabetes (T1D) is characterized by an increased risk of macrovascular complications. Pregnancy-associated plasma protein-A (PAPP-A) generated N- and C-terminal fragments of IGF binding protein-4 (NT-IGFBP-4 and CT-IGFBP-4) have been suggested as cardiac biomarkers. OBJECTIVE: The objective of the study was to investigate the prognostic value of IGFBP-4 fragments in a cohort of T1D patients. DESIGN AND PATIENTS: We prospectively followed up 178 T1D patients with diabetic nephropathy and 152 T1D patients with normoalbuminuria for 12.6 (range 0.2-12.9) years. MAIN OUTCOME MEASURES: Levels of IGF-1, IGF-2, IGFBP-1-4, NT- and CT-IGFBP-4, and PAPP-A at baseline. RESULTS: During follow-up, 15 patients with normoalbuminuria and 71 patients with nephropathy died. Of these deaths, 8 and 45 were due to fatal cardiovascular events, respectively. Using receiver-operating characteristic curve analyses, patients were divided into subgroups using cutoff values of 261 µg/L NT-IGFBP-4, 81 µg/L CT-IGFBP-4, or 10 mIU/L PAPP-A. All-cause mortality was significantly higher in patients with NT-IGFBP-4 levels (55% vs 16%, P < .001) and CT-IGFBP-4 levels (44% vs 15%, P < .001) above vs below cutoffs. Similarly, cardiovascular mortality was elevated in patients with high NT-IGFBP-4 levels (40% vs 7.8%, P < .001) and high CT-IGFBP-4 levels (30% vs 7.4%, P < .001). After adjustments for nephropathy and traditional cardiovascular risk factors, high NT- and CT-IGFBP-4 levels remained prognostic of cardiovascular mortality with hazard ratios [95% confidence interval (CI)] of 5.81 (95% CI 2.62-12.86) (P < .001) and 2.58 (95% CI 1.10-6.10) (P = .030), respectively. After adjustments, PAPP-A was not associated with overall or cardiovascular death. All IGF protein levels were higher in patients with diabetic nephropathy (P < .001), but no variables associated with mortality. CONCLUSION: High IGFBP-4 fragment levels were associated with increased all-cause and cardiovascular mortality rates in T1D patients with and without diabetic nephropathy.
Subject(s)
Biomarkers/blood , Cardiovascular Diseases/mortality , Diabetes Mellitus, Type 1/mortality , Diabetic Nephropathies/mortality , Insulin-Like Growth Factor Binding Protein 4/blood , Peptide Fragments/blood , Adult , Cardiovascular Diseases/blood , Cardiovascular Diseases/diagnosis , Cause of Death , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/diagnosis , Diabetic Nephropathies/blood , Diabetic Nephropathies/diagnosis , Female , Follow-Up Studies , Humans , Insulin-Like Growth Factor Binding Protein 4/chemistry , Male , Middle Aged , Pregnancy , Prognosis , Risk FactorsABSTRACT
The insulin-like growth factor (IGF) system is essential for normal growth and development, and its perturbation is implicated in a number of diseases. IGF activity is finely regulated by a family of six high-affinity IGF binding proteins (IGFBPs). 1GFBPs usually inhibit IGF actions but may enhance them under certain conditions. Additionally, IGFBPs bind non-IGF ligands in the extracellular space, cell membrane, cytoplasm and nucleus, thereby modulating cell proliferation, survival and migration in an IGF-independent manner. IGFBP activity is regulated by transcriptional mechanisms as well as by post-translational modifications and proteolysis. Understanding the balance between the various actions of IGFBPs in vivo may lead to novel insights into disease processes and possible IGFBP-based therapeutics.
Subject(s)
Insulin-Like Growth Factor Binding Proteins , Animals , Cell Physiological Phenomena/physiology , Humans , Insulin-Like Growth Factor Binding Protein 1/chemistry , Insulin-Like Growth Factor Binding Protein 1/physiology , Insulin-Like Growth Factor Binding Protein 2/chemistry , Insulin-Like Growth Factor Binding Protein 2/physiology , Insulin-Like Growth Factor Binding Protein 3/chemistry , Insulin-Like Growth Factor Binding Protein 3/physiology , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/physiology , Insulin-Like Growth Factor Binding Protein 5/chemistry , Insulin-Like Growth Factor Binding Protein 5/physiology , Insulin-Like Growth Factor Binding Protein 6/chemistry , Insulin-Like Growth Factor Binding Protein 6/physiology , Insulin-Like Growth Factor Binding Proteins/chemistry , Insulin-Like Growth Factor Binding Proteins/physiology , Molecular Structure , Somatomedins/physiologyABSTRACT
Insulin-like growth factor-binding proteins (IGFBPs) control bioactivity and distribution of insulin-like growth factors (IGFs) through high-affinity complex of IGFBP and IGF. To get more insight into the binding interaction of IGF system, the site-directed mutagenesis and force-driving desorption methods were employed to study the interaction mechanism of IGFBP4 and IGF-I by molecular dynamics (MD) simulation. In IGF-I, residues Gly7 to Asp12 were found to be the hot spots and they mainly anchored on the N-domain of IGFBP4. The contact area, the shape and size of protein, the surroundings of the binding site, the hydrophobic and electrostatic interaction between the two proteins worked as a complex network to regulate the protein-protein interaction. It was also found that the unfolding of the helix was not inevitable in the mutant, and it could be regulated by careful selection of the substituted amino acid.
Subject(s)
Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor I/chemistry , Molecular Dynamics Simulation , Amino Acid Substitution , Binding Sites , Humans , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor I/metabolism , Mutagenesis, Site-Directed , Mutation , Protein Interaction Maps , Protein Structure, SecondaryABSTRACT
The complete coding sequence of the porcine IBP4 gene was isolated using RT-PCR. Sequence analysis showed that the porcine IBP4 gene encodes a protein of 259 amino acids which shares high homology with the insulin-like growth factor binding protein 4 (IBP4) of eight species: cattle (97 %), goat (97 %), chimpanzee (97 %), human (96 %), giant panda (96 %), sheep (95 %), Sumatran orangutan (95 %) and rabbit (93 %). This gene is structured in four exons and three introns as revealed by computer- assisted analysis. Phylogenetic analysis revealed that the porcine IBP4 gene has a close genetic relationship with the IBP4 gene of cattle. Polymorphism analysis indicated that there was an A/G substitution in the position of 134 bp of exon 2 and this mutation did not alter the encoded amino acids of the porcine IBP4 gene. PCR-Hha I-RFLP revealed that eight pig breeds displayed obvious genotype and allele frequency differences at this polymorphic locus. Association of this SNP with litter size traits was assessed in Large White (N = 100) and Landrace (N = 100) populations, and the results demonstrated that this polymorphic locus was significantly associated with the litter size of the first parity in Large White sows and Landrace sows (P <0.05). These data serve as a foundation for further insight into this novel porcine gene.
Subject(s)
Genetic Association Studies , Insulin-Like Growth Factor Binding Protein 4/genetics , Polymorphism, Restriction Fragment Length/genetics , Sus scrofa/genetics , Amino Acid Sequence , Animals , Base Sequence , Breeding , DNA, Complementary/genetics , Deoxyribonucleases, Type II Site-Specific/metabolism , Gene Frequency , Genetic Loci/genetics , Genotype , Humans , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/metabolism , Litter Size/genetics , Molecular Sequence Data , Open Reading Frames/genetics , Phylogeny , Quantitative Trait, Heritable , Reverse Transcriptase Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNAABSTRACT
The establishment of cardiomyocyte differentiation of embryonic stem cells (ESCs) is a useful strategy for cardiovascular regenerative medicine. Here, we report a strategy for cardiomyocyte differentiation of ESCs using substrate immobilization of insulin-like growth factor binding protein 4 (IGFBP4) with elastin-like polypeptides. Recently, IGFBP4 was reported to promote cardiomyocyte differentiation of ESCs through inhibition of the Wnt/ß-catenin signaling. However, high amounts of IGFBP4 (approximately 1 µg/mL) were required to inhibit the Wnt/ß-catenin signaling and induce differentiation to cardiomyocytes. We report herein induction of cardiomyocyte differentiation using IGFBP4-immobilized substrates. IGFBP4-immobilized substrates were created by fusion with elastin-like polypeptides. IGFBP4 was stably immobilized to polystyrene dishes through fusion of elastin-like polypeptides. Cardiomyocyte differentiation of ESCs was effectively promoted by strong and continuous inhibition of Wnt/ß-catenin signaling with IGFBP4-immobilized substrates. These results demonstrated that IGFBP4 could be immobilized using fusion of elastin-like polypeptides. Our results also demonstrate that substrate immobilization of IGFBP4 is a powerful tool for differentiation of ESCs into cardiomyocytes. These findings suggest that substrate immobilization of soluble factors is a useful technique for differentiation of ESCs in regenerative medicine and tissue engineering.
Subject(s)
Cell Differentiation , Embryonic Stem Cells/cytology , Immobilized Proteins/chemistry , Insulin-Like Growth Factor Binding Protein 4/chemistry , Myocytes, Cardiac/cytology , Animals , Biopolymers/metabolism , Blotting, Western , Cell Line, Tumor , Elastin/chemistry , Immunoprecipitation , Mice , Mice, Inbred C3H , Peptides/metabolism , Plasmids , Recombinant Proteins , Signal Transduction , Tissue Engineering , Wnt Proteins/antagonists & inhibitors , Wnt Proteins/genetics , Wnt Proteins/metabolism , beta Catenin/antagonists & inhibitors , beta Catenin/genetics , beta Catenin/metabolismABSTRACT
Proteolysis is a major protein posttranslational modification that, by altering protein structure, affects protein function and, by truncating the protein sequence, alters peptide signatures of proteins analyzed by proteomics. To identify such modified and shortened protease-generated neo-N-termini on a proteome-wide basis, we developed a whole protein isobaric tag for relative and absolute quantitation (iTRAQ) labeling method that simultaneously labels and blocks all primary amines including protein N- termini and lysine side chains. Blocking lysines limits trypsin cleavage to arginine, which effectively elongates the proteolytically truncated peptides for improved MS/MS analysis and peptide identification. Incorporating iTRAQ whole protein labeling with terminal amine isotopic labeling of substrates (iTRAQ-TAILS) to enrich the N-terminome by negative selection of the blocked mature original N-termini and neo-N-termini has many advantages. It enables simultaneous characterization of the natural N-termini of proteins, their N-terminal modifications, and proteolysis product and cleavage site identification. Furthermore, iTRAQ-TAILS also enables multiplex N-terminomics analysis of up to eight samples and allows for quantification in MS2 mode, thus preventing an increase in spectral complexity and extending proteome coverage by signal amplification of low abundance proteins. We compared the substrate degradomes of two closely related matrix metalloproteinases, MMP-2 (gelatinase A) and MMP-9 (gelatinase B), in fibroblast secreted proteins. Among 3,152 unique N-terminal peptides identified corresponding to 1,054 proteins, we detected 201 cleavage products for MMP-2 and unexpectedly only 19 for the homologous MMP-9 under identical conditions. Novel substrates identified and biochemically validated include insulin-like growth factor binding protein-4, complement C1r component A, galectin-1, dickkopf-related protein-3, and thrombospondin-2. Hence, N-terminomics analyses using iTRAQ-TAILS links gelatinases with new mechanisms of action in angiogenesis and reveals unpredicted restrictions in substrate repertoires for these two very similar proteases.
Subject(s)
Isotope Labeling/methods , Matrix Metalloproteinase 2/chemistry , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/chemistry , Matrix Metalloproteinase 9/metabolism , Protein Processing, Post-Translational , Proteomics/methods , Amino Acid Sequence , Animals , Fibroblasts/enzymology , Fibroblasts/metabolism , Galectin 1/chemistry , Galectin 1/metabolism , Humans , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/metabolism , Matrix Metalloproteinase 2/deficiency , Mice , Molecular Sequence Data , Peptides/chemistry , Peptides/metabolism , Reproducibility of Results , Sequence Analysis, Protein , Substrate Specificity , Thrombospondins/chemistry , Thrombospondins/metabolismABSTRACT
The insulin-like growth factor (IGF) signaling pathway is a conserved pathway that regulates animal development, growth, metabolism, reproduction, and aging. The biological actions of IGFs are modulated by IGF-binding proteins (IGFBPs). Although the structure and function of fish IGFBP-1, -2, -3, and -5 have been elucidated, there is currently no report on the full-length structure of a fish IGFBP-4 nor its biological action. In this study, we cloned and characterized the IGFBP-4 gene from fugu. Sequence comparison, phylogenetic, and synteny analyses indicate that its chromosomal location, gene, and protein structure are similar to its mammalian orthologs. Fugu IGFBP-4 mRNA was easily detectable in all adult tissues examined with the exception of spleen. Older animals tended to have higher levels of IGFBP-4 mRNA in the muscle and eyes compared with younger animals. Starvation resulted in significant increases in IGFBP-4 mRNA abundance in the muscle, liver, gallbladder, and brain. Overexpression of fugu and human IGFBP-4 in zebrafish embryos caused a significant decrease in body size and somite number, suggesting that fugu IGFBP-4 inhibits growth and development, possibly by binding to IGFs and inhibiting their binding to the IGF receptors. These results provide new information about the structural and functional conservation, expression patterns, and physiological regulation of the IGFBP-4 gene in a teleost fish.
Subject(s)
Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 4/physiology , Takifugu/physiology , Amino Acid Sequence , Animals , Blotting, Western , Body Size , Cloning, Molecular , DNA, Complementary/biosynthesis , DNA, Complementary/genetics , Gene Expression , Humans , Insulin-Like Growth Factor Binding Protein 4/chemistry , Molecular Sequence Data , RNA/biosynthesis , RNA/genetics , Reverse Transcriptase Polymerase Chain Reaction , ZebrafishABSTRACT
The metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) cleaves both insulin-like growth factor (IGF)-binding protein 4 (IGFBP-4) and -5 at a single site in their central domain causing the release of bioactive IGF. Inhibition of IGF signaling is relevant in human disease, and several drugs in development target the IGF receptor. However, inhibition of PAPP-A activity may be a valuable alternative. We have generated monoclonal phage-derived single chain fragment variable (scFv) antibodies which selectively inhibit the cleavage of IGFBP-4 by PAPP-A, relevant under conditions where cleavage of IGFBP-4 represents the final step in the delivery of IGF to the IGF receptor. None of the antibodies inhibited the homologous proteinase PAPP-A2, which allowed mapping of antibody binding by means of chimeras between PAPP-A and PAPP-A2 to the C-terminal Lin12-Notch repeat module, separated from the proteolytic domain by almost 1000 amino acids. Hence, the antibodies define a substrate binding exosite that can be targeted for the selective inhibition of PAPP-A proteolytic activity against IGFBP-4. In addition, we show that the Lin12-Notch repeat module reversibly binds a calcium ion and that bound calcium is required for antibody binding, providing a strategy for the further development of selective inhibitory compounds. To our knowledge these data represent the first example of differential inhibition of cleavage of natural proteinase substrates by exosite targeting. Generally, exosite inhibitors are less likely to affect the activity of related proteolytic enzymes with similar active site environments. In the case of PAPP-A, selective inhibition of IGFBP-4 cleavage by interference with exosite binding is a further advantage, as the activity against other known or unknown PAPP-A substrates, whose cleavage may not depend on binding to the same exosite, is not targeted.
Subject(s)
Pregnancy-Associated Plasma Protein-A/metabolism , Animals , Antibodies, Monoclonal/chemistry , Binding Sites , Cell Line , Chickens , Humans , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor I/metabolism , Models, Genetic , Peptide Library , Pregnancy-Associated Plasma Protein-A/chemistry , Protein Binding , Protein Structure, Tertiary , Surface Plasmon ResonanceABSTRACT
IGF-I has been shown to play a role in the progression of atherosclerosis in experimental animal models. IGF-binding protein-4 (IGFBP-4) binds to IGF-I and prevents its association with receptors. Overexpression of a protease-resistant form of IGFBP-4 has been shown to inhibit the ability of IGF-I to stimulate normal smooth muscle cell growth in mice. Based on these observations, we prepared a protease-resistant form of IGFBP-4 and infused it into hypercholesterolemic pigs. Infusion of the protease-resistant mutant inhibited lesion development by 53.3 +/- 6.1% (n = 6; P < 0.01). Control vessels that received an equimolar concentration of IGF-I and the protease-resistant IGFBP-4 showed no reduction in lesion size compared with control lesions that were infused with vehicle. Infusion of a nonmutated form of IGFBP-4 did not significantly inhibit lesion development. Proliferating cell nuclear antigen analysis showed that the mutant IGFBP-4 appeared to inhibit cell proliferation. The area occupied by extracellular matrix was also reduced proportionally compared with total lesion area. Immunoblotting revealed that the mutant IGFBP-4 remained intact, whereas the wild-type IGFBP-4 that was infused was proteolytically cleaved. Further analysis of the lesions revealed that a marker protein, IGFBP-5, whose synthesis is stimulated by IGF-I, was decreased in the lesions that received the protease-resistant, IGFBP-4 mutant, whereas there was no change in lesions that received wild-type IGFBP-4 or the mutant protein plus IGF-I. These findings clearly illustrate that infusion of protease-resistant IGFBP-4 into the perilesion environment results in inhibition of cell proliferation and attenuation of the development of neointima. The findings support the hypothesis that inhibiting IGFBP-4 proteolysis in the lesion microenvironment could be an effective means for regulating neointimal expansion.
Subject(s)
Hypercholesterolemia/pathology , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/pharmacology , Insulin-Like Growth Factor I/antagonists & inhibitors , Peptide Hydrolases/metabolism , Tunica Intima/pathology , Animals , Carotid Arteries/drug effects , Carotid Arteries/metabolism , Carotid Arteries/pathology , Cell Proliferation/drug effects , Drug Resistance , Female , Femoral Artery/drug effects , Femoral Artery/metabolism , Femoral Artery/pathology , Hypercholesterolemia/metabolism , Hyperplasia , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 5/antagonists & inhibitors , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor I/pharmacology , Male , Mutation , Swine , Transfection , Tunica Intima/drug effects , Tunica Intima/metabolismABSTRACT
BACKGROUND: Maternal serum concentrations of pregnancy-associated plasma protein-A (PAPP-A, pappalysin-1, EC 3.4.24.79) are used to predict the occurrence of Down syndrome. In pregnancy, PAPP-A primarily circulates as a covalent 2:2 complex with the proform of eosinophil major basic protein (proMBP), which inhibits the proteolytic activity of PAPP-A. At term, however, approximately 1% of PAPP-A exists as an active, uncomplexed dimer with proteolytic activity directed specifically toward insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5. No assays have been developed that allow quantification of PAPP-A proteolytic activity. METHODS: We developed a sensitive and specific immunocapture assay for PAPP-A activity based on intramolecular quenched fluorescence. We used a 26-residue synthetic peptide derived from IGFBP-4 in which specific positions on each side of the PAPP-A cleavage site were substituted with 3-nitrotyrosine and o-aminobenzoic acid. RESULTS: The assay detected the activity of recombinant PAPP-A as well as PAPP-A in serum samples from pregnant women. The limit of detection (mean signal of blank plus 3 SD) of the active PAPP-A subunit was 13 pmol/L, and the intra- and interassay CVs were <10% and <15%, respectively. Interestingly, the fraction of active PAPP-A decreased gradually from week 7 to week 19 of pregnancy. CONCLUSIONS: This method allows the measurement of PAPP-A enzymatic activity and because of its specificity it is relevant to the study of the biological function of PAPP-A. The method may also be useful in the diagnosis of pregnancy disorders.
Subject(s)
Pregnancy-Associated Plasma Protein-A/analysis , Prenatal Diagnosis/methods , Antibodies, Monoclonal , Female , Fluorescence , Humans , Hydrolysis , Immunoassay , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/metabolism , Kinetics , Peptides/chemistry , Pregnancy , Pregnancy Trimester, First , Pregnancy Trimester, Second , Pregnancy-Associated Plasma Protein-A/chemistry , Pregnancy-Associated Plasma Protein-A/immunology , Protein Subunits/analysis , Recombinant Proteins/analysis , Sensitivity and Specificity , Tyrosine/analogs & derivatives , Tyrosine/chemistry , ortho-Aminobenzoates/chemistryABSTRACT
The metzincin metalloproteinase pregnancy-associated plasma protein-A (PAPP-A, pappalysin-1, EC 3.4.24.79) specifically cleaves insulin-like growth factor binding protein (IGFBP)-4 and -5. Regulation of insulin-like growth factor (IGF) bioavailability through cleavage of these inhibitory binding proteins is an important mechanism for the control of growth and development of vertebrate cells. Although proteolysis of IGFBP-4 and -5 by PAPP-A has been extensively studied in many systems, quantitative analyses have been lacking. We have characterized the cleavage of its natural substrates, IGFBP-4 and -5, in the absence and presence of IGF-I or -II and determined the kinetic parameters (Km and kcat) for the different combinations of IGFBP and IGF. The rate of IGFBP-4 proteolysis is dramatically increased upon addition of IGF-I or -II. Kinetic analysis revealed that IGF-II was a more potent activator of IGFBP-4 proteolysis than IGF-I. Proteolysis of IGFBP-5 is slightly inhibited by IGF, and we find that IGF-I and -II display a similar degree of inhibition of IGFBP-5 cleavage. We show that the mechanism of IGF-modulated proteolysis of IGFBP-4 and -5 involves changes in both the recognition of substrate (Km) and the turnover rate (kcat). In addition, we have devised a novel method of revealing potential consequences of substrate modification for kinetic analysis, and we have used this method to establish that there is no apparent difference in the behavior of radiolabeled IGFBP-4 and -5 compared to the behavior of the unmodified protein substrates. We also propose experimental conditions for the proper analysis of IGFBP proteolysis, and we demonstrate their usefulness by quantitatively evaluating the effect of inhibitory compounds on the rate of proteolysis. Finally, we have compared PAPP-A to other proteinases thought to have IGFBP-4 or -5 as a substrate. This emphasizes the potential of PAPP-A to specifically and efficiently function as a regulator in the IGF system.
Subject(s)
Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 5/chemistry , Insulin-Like Growth Factor II/chemistry , Insulin-Like Growth Factor I/chemistry , Pregnancy-Associated Plasma Protein-A/chemistry , KineticsABSTRACT
Insulin-like growth factor-binding proteins (IGFBPs) control bioavailability, activity, and distribution of insulin-like growth factor (IGF)1 and -2 through high-affinity IGFBP/IGF complexes. IGF-binding sites are found on N- and C-terminal fragments of IGFBPs, the two conserved domains of IGFBPs. The relative contributions of these domains to IGFBP/IGF complexation has been difficult to analyze, in part, because of the lack of appropriate three-dimensional structures. To analyze the effects of N- and C-terminal domain interactions, we determined several x-ray structures: first, of a ternary complex of N- and C-terminal domain fragments of IGFBP4 and IGF1 and second, of a "hybrid" ternary complex using the C-terminal domain fragment of IGFBP1 instead of IGFBP4. We also solved the binary complex of the N-terminal domains of IGFBP4 and IGF1, again to analyze C- and N-terminal domain interactions by comparison with the ternary complexes. The structures reveal the mechanisms of IGF signaling regulation via IGFBP binding. This finding supports research into the design of IGFBP variants as therapeutic IGF inhibitors for diseases of IGF disregulation. In IGFBP4, residues 1-38 form a rigid disulphide bond ladder-like structure, and the first five N-terminal residues bind to IGF and partially mask IGF residues responsible for the type 1 IGF receptor binding. A high-affinity IGF1-binding site is located in a globular structure between residues 39 and 82. Although the C-terminal domains do not form stable binary complexes with either IGF1 or the N-terminal domain of IGFBP4, in the ternary complex, the C-terminal domain contacts both and contributes to blocking of the IGF1 receptor-binding region of IGF1.
Subject(s)
Insulin-Like Growth Factor Binding Protein 1/chemistry , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor I/chemistry , Amino Acid Sequence , Humans , Insulin-Like Growth Factor Binding Protein 1/metabolism , Insulin-Like Growth Factor Binding Protein 4/metabolism , Models, Molecular , Molecular Sequence Data , Protein Binding , Protein Folding , Protein Structure, Secondary , Protein Structure, Tertiary , Structure-Activity RelationshipABSTRACT
Calpains are non-lysosomal, Ca 2+ -dependent cysteine proteases, which are ubiquitously distributed across cell types and vertebrate species. The rules that govern calpain specificity have not yet been determined. To elucidate the cleavage pattern of calpains, we carried out calpain-induced proteolytic studies on the insulin-like growth factor binding proteins IGFBP-4 and -5. Proteolysis of IGFBPs is well characterized in numerous reports. Our results show that calpain cleavage sites are in the non-conserved unstructured regions of the IGFBPs. Compilation of the calpain-induced proteolytic cleavage sites in several proteins reported in the literature, together with our present study, has not revealed clear preferences for amino acid sequences. We therefore conclude that calpains seem not to recognize amino acid sequences, but instead cleave with low sequence specificity at unstructured or solvent-exposed fragments that connect folded, stable domains of target proteins.
Subject(s)
Calpain/chemistry , Insulin-Like Growth Factor Binding Proteins/chemistry , Amino Acid Sequence , Cloning, Molecular , Gene Expression Regulation , Humans , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor Binding Protein 5/chemistry , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 5/metabolism , Insulin-Like Growth Factor Binding Proteins/genetics , Insulin-Like Growth Factor Binding Proteins/metabolism , Molecular Sequence Data , Protein Folding , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Alignment , Substrate Specificity/physiologyABSTRACT
Insulin-like growth factor-binding proteins play a critical role in a wide variety of important physiological processes. It has been demonstrated that both an N-terminal and a C-terminal fragment of insulin-like growth factor-binding protein-4 exist and accumulate in the circulatory system, these fragments accounting for virtually the whole amino acid sequence of the protein. The circulating C-terminal fragment establishes three disulfide bridges, and the binding pattern of these has recently been defined. Here we show that the monodimensional 1H NMR spectrum of the C-terminal fragment is typical of a protein with a relatively close packed tertiary structure. This fragment can be produced in its native conformation in Escherichia coli, without the requirement of further refolding procedures, when synthesis is coupled to its secretion from the cell. The recombinant protein crystallizes with the unit cell parameters of a hexagonal system. Furthermore, it binds strongly to heparin, acquiring a well defined oligomeric structure that interacts with insulin-like growth factors, and promotes bone formation in cultures of murine calvariae.
Subject(s)
Heparin/chemistry , Insulin-Like Growth Factor Binding Protein 4/blood , Insulin-Like Growth Factor Binding Protein 4/chemistry , Amino Acid Sequence , Animals , Base Sequence , Bone Development , Bone and Bones/metabolism , Chromatography , Cloning, Molecular , Crystallography, X-Ray , Disulfides , Escherichia coli/metabolism , Magnetic Resonance Spectroscopy , Mice , Molecular Conformation , Molecular Sequence Data , Protein Binding , Protein Conformation , Protein Structure, Tertiary , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Time Factors , UltracentrifugationABSTRACT
Insulin-like growth factor binding proteins (IGFBPs) control the extracellular distribution, function, and activity of IGFs. Here, we report an X-ray structure of the binary complex of IGF-I and the N-terminal domain of IGFBP-4 (NBP-4, residues 3-82) and a model of the ternary complex of IGF-I, NBP-4, and the C-terminal domain (CBP-4, residues 151-232) derived from diffraction data with weak definition of the C-terminal domain. These structures show how the IGFBPs regulate IGF signaling. Key features of the structures include (1) a disulphide bond ladder that binds to IGF and partially masks the IGF residues responsible for type 1 IGF receptor (IGF-IR) binding, (2) the high-affinity IGF-I interaction site formed by residues 39-82 in a globular fold, and (3) CBP-4 interactions. Although CBP-4 does not bind individually to either IGF-I or NBP-4, in the ternary complex, CBP-4 contacts both and also blocks the IGF-IR binding region of IGF-I.
Subject(s)
Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 5/chemistry , Insulin-Like Growth Factor Binding Proteins/chemistry , Amino Acid Sequence , Binding Sites , Calorimetry , Crystallography, X-Ray , Humans , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 5/metabolism , Insulin-Like Growth Factor Binding Proteins/metabolism , Kinetics , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Nuclear Magnetic Resonance, Biomolecular , Peptide Fragments/metabolism , Phosphorylation , Protein Binding , Protein Structure, Tertiary , Receptor, IGF Type 1/metabolism , Sequence Homology, Amino AcidABSTRACT
Bovine follicular atresia is associated with the apoptosis of granulosa cells and the subsequent loss of oocyte competence through the reduction of cellular contact (e.g., gap junctions). Several components of the insulin-like growth factor (IGF) system are thought to affect follicular atresia. Whereas the IGF-binding proteins (IGFBPs) are present in varying quantities throughout follicular development, IGFBP-5 appears to be present only during atresia, in parallel with its regulation in other tissue remodeling systems. However, to our knowledge, no connection has yet been made between atresia, low-molecular-weight IGFBP content, and oocyte quality in the bovine ovary. Caspases are actively involved in ovarian follicular atresia, and apoptosis in antral follicles is caspase-3-dependent. Hence, the aim of the present study was to investigate the use of these factors in the assessment of oocyte quality and developmental potential. Oocytes were aspirated, morphologically classified, and individually matured in vitro. The follicular fluid and granulosa cells of these follicles were analyzed for IGFBP profile and caspase-3 activity, respectively. A significant correlation was found between the presence of low-molecular-weight IGFBPs in bovine follicular fluid and caspase-3 activity of granulosa cells isolated from individual follicles. The highest percentage of development to the blastocyst stage was observed in oocytes from slightly atretic follicles. This group of oocytes contained an equal proportion of oocytes at grades 1-3. These data demonstrate that low-molecular-weight IGFBP profile is a more reliable method than the traditional morphological assessment of oocytes and can be used as an effective marker of developmentally competent oocytes. Importantly, these results have implications for the use of noninvasive follicular fluid markers in the selection of competent oocytes to improve outcomes of in vitro fertilization.
Subject(s)
Caspases/metabolism , Fertilization in Vitro , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor Binding Protein 5/metabolism , Oocytes/cytology , Animals , Biomarkers/metabolism , Caspase 3 , Cattle , Cell Survival , Female , Follicular Atresia/metabolism , Insulin-Like Growth Factor Binding Protein 2/chemistry , Insulin-Like Growth Factor Binding Protein 2/metabolism , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 5/chemistry , Molecular Weight , Oocytes/metabolism , Ovarian Follicle/cytology , Ovarian Follicle/metabolismABSTRACT
Insulin-like growth factor binding protein (IGFBP)-5 is a conserved protein synthesized and secreted by vascular smooth muscle cells (VSMCs). IGFBP-5 binds to extracellular IGFs and modulates IGF actions in regulating VSMC proliferation, migration, and survival. IGFBP-5 also stimulates VSMC migration through an IGF-independent mechanism, but the molecular basis underlying this ligand-independent action is unknown. In this study, we show that endogenous IGFBP-5 or transiently expressed IGFBP-5-EGFP, but not IGFBP-4-EGFP, is localized in the nuclei of VSMCs. Using a series of IGFBP-4/5 chimeras and IGFBP-5 points mutants, we demonstrated that the IGFBP-5 C-domain is necessary and sufficient for its nuclear localization, and residues K206, K208, K217, and K218 are particularly critical. Intriguingly, inhibition of protein secretion abolishes IGFBP-5 nuclear localization, suggesting the nuclear IGFBP-5 is derived from the secreted protein. When added exogenously, (125)I- or Cy3-labeled IGFBP-5 is capable of cellular entry and nuclear translocation. To identify potential transcriptional factor(s) that interact with IGFBP-5, a human aorta cDNA library was screened by a yeast two-hybrid screening strategy. Although this screen identified many extracellular and cytosolic proteins that are known to interact with IGFBP-5, no known transcription factors were found. Further motif analysis revealed that the IGFBP-5 N-domain contains a putative transactivation domain. When fused to GAL-4 DNA dinging domain and tested, the IGFBP-5 N-domain has strong transactivation activity. Mutation of the IGF binding domain or treatment of cells with IGF-I has little effect on transactivation activity. These results suggest that IGFBP-5 is localized in VSMC nucleus and possesses transcription-regulatory activity that is IGF independent.
Subject(s)
Cell Nucleus/chemistry , Insulin-Like Growth Factor Binding Protein 5/physiology , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/metabolism , Transcriptional Activation , Amino Acid Motifs , Animals , CHO Cells , Cell Line , Cricetinae , Cricetulus , DNA, Complementary/genetics , Endocytosis , Evolution, Molecular , Humans , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 5/biosynthesis , Insulin-Like Growth Factor Binding Protein 5/chemistry , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 5/pharmacology , Myocytes, Smooth Muscle/ultrastructure , Point Mutation , Protein Structure, Tertiary , Protein Transport , Rabbits , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/physiology , Sequence Homology, Amino Acid , Species Specificity , Swine , Transcriptional Activation/drug effects , Transcriptional Activation/physiology , Transfection , Zebrafish/geneticsABSTRACT
Development of a dominant follicle is associated with decreased intrafollicular low molecular weight IGF-binding proteins (namely IGFBP-2, -4, and -5) and increased proteolysis of IGFBP-4 by pregnancy-associated plasma protein A (PAPP-A). In addition to IGFBP-4 proteolytic activity, bovine follicular fluid contains strong proteolytic activity for IGFBP-5, but not for IGFBP-2. Here we show that the IGFBP-5 protease present in bovine follicular fluid is a neutral/basic pH-favoring, Zn(2+) metalloprotease very similar to the previously described IGFBP-4 protease. We hypothesized that immunoneutralization and immunoprecipitation with anti-PAPP-A antibodies would result in abrogation of the IGFBP-4, but not the IGFBP-5, proteolytic activity in follicular fluid. As expected, anti-PAPP-A antibodies were able to neutralize and precipitate the IGFBP-4, but not the IGFBP-5, proteolytic activity of human pregnancy serum, which was used as a positive control for PAPP-A. Surprisingly, immunoneutralization and immunoprecipitation of follicular fluid from bovine preovulatory follicles with anti-PAPP-A antibodies abrogated both IGFBP-4 and IGFBP-5 proteolysis. Quantitative results derived from phosphorimaging revealed a complete inhibition of both IGFBP-4 and -5 proteolysis by follicular fluid incubated for 2 or 5 h in the presence of anti-PAPP-A antibodies. After 18 h of incubation, anti-PAPP-A antibodies still inhibited IGFBP-5 degradation, although with an efficiency lower than that for IGFBP-4 degradation. Both proteolytic activities have identical electrophoretic mobility, and a single band ( approximately 400 kDa) was detected by Western immunoblotting of bovine follicular fluid with anti-PAPP-A antibodies. Proteolysis of IGFBP-5 was readily detectable in follicular fluid from dominant follicles and was negligible in subordinate follicles from the same cohort. These results suggest that an active intrafollicular IGFBP-4/-5 proteolytic system, in which PAPP-A is the major protease involved, is an important determinant of follicular fate.
Subject(s)
Follicular Fluid/metabolism , Insulin-Like Growth Factor Binding Protein 5/metabolism , Ovarian Follicle/metabolism , Pregnancy-Associated Plasma Protein-A/metabolism , Animals , Antibody Specificity , Cattle , Corpus Luteum/physiology , Electrophoresis , Female , Follicular Fluid/diagnostic imaging , Follicular Phase , Humans , Insulin-Like Growth Factor Binding Protein 2/metabolism , Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 4/immunology , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor Binding Protein 5/chemistry , Insulin-Like Growth Factor Binding Protein 5/immunology , Molecular Weight , Ovarian Follicle/diagnostic imaging , Precipitin Tests , Pregnancy , Pregnancy-Associated Plasma Protein-A/immunology , UltrasonographyABSTRACT
Insulin-like growth factor binding protein 6 (IGFBP-6) is a high-affinity IGFBP with substantially greater affinity for insulin-like growth factor-II (IGF-II) than IGF-I. IGFBP-6(3) is a chimera which has a 20 amino acidC -terminal portion of IGFBP-6 switched with the homologous area of IGFBP-3, P3. Unlike IGFBP-4(3), in which the P3 region was exchanged for the homologous region of IGFBP-4 (P4), IGFBP-6(3) does not bind to endothelial cells. Double mutations were made with the P3 region exchanged as well as a second area differing from IGFBP-3 to form IGFBP-6(3)A and IGFBP-6(3)B, by replacing this area with the homologous region of IGFBP-3. Neither [(125)I]IGFBP-6(3)A nor IGFBP-6(3)B specifically bound to endothelial cells. However, each double mutant competed for [(125)I]IGFBP-3 binding to cultured cells. In the perfused heart, transendothelial transport of IGFBP-6 and IGFBP-6(3) was only 25% of similar transendothelial transport of perfused IGFBP-3. We conclude that chimeras of IGFBP-6 and IGFBP-3(6) clearly differ from IGFBP-4(3) in their ability to bind specifically to endothelial cells and in their capacity to undergo transendothelial transportation in the perfused heart.
Subject(s)
Insulin-Like Growth Factor Binding Protein 4/chemistry , Insulin-Like Growth Factor Binding Protein 6/chemistry , Insulin-Like Growth Factor Binding Protein 6/physiology , Amino Acid Sequence , Animals , Cattle , Cells, Cultured , Dose-Response Relationship, Drug , Endothelium/cytology , Endothelium, Vascular/cytology , Heart/physiology , Insulin-Like Growth Factor Binding Protein 4/metabolism , Insulin-Like Growth Factor II/metabolism , Ligands , Molecular Sequence Data , Mutation , Perfusion , Protein Binding , Protein Structure, Tertiary , Rats , Sequence Homology, Amino Acid , Structure-Activity RelationshipABSTRACT
Insulin-like growth factor binding protein-4 (IGFBP-4) is, like the other five IGFBPs, a critical regulator of the activity of insulin-like growth factor (IGF)-I and IGF-II. Whereas IGFBP-1 and IGFBP-2 are not glycosylated, IGFBP-3 and IGFBP-4 are N-glycosylated and IGFBP-5 and IGFBP-6 are O-glycosylated. In this study we identified the glycosylation of IGFBP-4 using a nanoflow LC/MS/MS techniques. Although N-linked oligosaccharides are structurally diverse, their variants are well reported in the literature. Based on the molecular weight of the possible oligosaccharide moieties, we identified five different glycosylation isoforms of the protein. Identified glycans were biantennary and differ in the number of sialic acid terminal residues and/or core modification with fucose.